Captrust Financial Advisors Has $3.36 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Captrust Financial Advisors reduced its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 31,795 shares of the medical equipment provider’s stock after selling 1,919 shares during the period. Captrust Financial Advisors’ holdings in Zimmer Biomet were worth $3,358,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nordea Investment Management AB boosted its position in shares of Zimmer Biomet by 3.9% in the 4th quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 609 shares during the last quarter. ORG Partners LLC grew its position in shares of Zimmer Biomet by 14,497.5% during the 4th quarter. ORG Partners LLC now owns 5,839 shares of the medical equipment provider’s stock worth $617,000 after buying an additional 5,799 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Zimmer Biomet by 8.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 15,845 shares of the medical equipment provider’s stock valued at $1,710,000 after acquiring an additional 1,173 shares during the last quarter. Czech National Bank raised its position in shares of Zimmer Biomet by 4.0% in the 4th quarter. Czech National Bank now owns 43,164 shares of the medical equipment provider’s stock valued at $4,559,000 after acquiring an additional 1,678 shares during the period. Finally, Brookstone Capital Management boosted its stake in Zimmer Biomet by 34.3% during the 4th quarter. Brookstone Capital Management now owns 8,581 shares of the medical equipment provider’s stock worth $906,000 after acquiring an additional 2,193 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 0.1 %

Zimmer Biomet stock opened at $95.22 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company’s 50-day moving average is $104.43 and its 200-day moving average is $106.12. The firm has a market capitalization of $18.84 billion, a PE ratio of 21.40, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.92 and a fifty-two week high of $122.25.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The business’s revenue was up 1.1% on a year-over-year basis. During the same period last year, the firm posted $1.94 earnings per share. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.24%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ZBH shares. Robert W. Baird cut their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. BTIG Research reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Wells Fargo & Company decreased their target price on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Morgan Stanley cut their price objective on Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Finally, Barclays lowered their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $114.15.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.39% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.